<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="RoActemra; Tocilizumab" /><meta name="IX" content="RoActemra; Tocilizumab" /><title>RoActemra®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="204108.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="204108.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=204108.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a> &gt; <a href="202659.htm">Cytokine modulators</a> &gt; <a href="203908.htm">TOCILIZUMAB</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="129937.htm" title="Previous: RITUXIMAB">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="5307.htm" title="Next: Sulfasalazine">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a310009.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tocilizumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Miscellaneous Therapeutic Agents 92:00 &gt; Disease-modifying Antirheumatic Drugs 92:36</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22508-r.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tocilizumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: T &gt; Interactions of Tocilizumab</p></div></li></ul><ul><li><h3>British National Formulary (3)</h3></li><li><a href="202659.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Cytokine modulators</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 10 Musculoskeletal and joint diseases &gt; 10.1 Drugs used in rheumatic diseases and gout &gt; 10.1.3 Drugs that suppress the rheumatic disease process</p></div></li><li><a href="203908.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">TOCILIZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 10 Musculoskeletal and joint diseases &gt; 10.1 Drugs used in rheumatic diseases and gout &gt; 10.1.3 Drugs that suppress the rheumatic disease process &gt; Cytokine modulators</p></div></li><li><a href="204124.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tocilizumab</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; Appendix 4 Intravenous additives &gt; Use of table &gt; Table of drugs given by intravenous infusion</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/ms-25035-v.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interleukin-6 Receptor Antagonists</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Miscellaneous Drugs and Other Substances &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/09493.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Tocilizumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; T &gt; TO</p></div></li></ul><ul><li><h3>Rules &amp; Guidance for Pharmaceutical Manufacturers &amp; Distributors (6)</h3></li><li><a href="http://www.medicinescomplete.com/mc/orange/2009/c02sec1168.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">

Release of Batches</a><div class="breadcrumb"><p><strong>Rules &amp; Guidance for Pharmaceutical Manufacturers &amp; Distributors</strong> &gt; II  GUIDANCE ON GOOD MANUFACTURING PRACTICE (GMP) &gt; 2  EU Guidance on Good Manufacturing
Practice &gt; PART I:  Basic Requirements for Medicinal
Products &gt; ANNEX 13  
INVESTIGATIONAL MEDICINAL PRODUCTS</p></div></li><li><a href="http://www.medicinescomplete.com/mc/orange/2009/c02sec1200.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">7  Batch Testing and Release of Products Imported from a Third
Country with which the EC has a Mutual Recognition Agreement (MRA)</a><div class="breadcrumb"><p><strong>Rules &amp; Guidance for Pharmaceutical Manufacturers &amp; Distributors</strong> &gt; II  GUIDANCE ON GOOD MANUFACTURING PRACTICE (GMP) &gt; 2  EU Guidance on Good Manufacturing
Practice &gt; PART I:  Basic Requirements for Medicinal
Products &gt; ANNEX 16  CERTIFICATION BY A QUALIFIED PERSON AND BATCH RELEASE</p></div></li><li><a href="http://www.medicinescomplete.com/mc/orange/2009/c02sec1202.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">9  Glossary</a><div class="breadcrumb"><p><strong>Rules &amp; Guidance for Pharmaceutical Manufacturers &amp; Distributors</strong> &gt; II  GUIDANCE ON GOOD MANUFACTURING PRACTICE (GMP) &gt; 2  EU Guidance on Good Manufacturing
Practice &gt; PART I:  Basic Requirements for Medicinal
Products &gt; ANNEX 16  CERTIFICATION BY A QUALIFIED PERSON AND BATCH RELEASE</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22tocilizumab%22%22tocilizumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (6)</a></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D2265.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Tocilizumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; T</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_203908">TOCILIZUMAB</h1><div id="pC" class="jN"><div class="cAJ"><span class="cAD">Additional information</span> interactions (<a href="41001i1161.htm" title="Go to appendix 1">Tocilizumab</a>).</div><div class="cAF"><h2>Indications</h2> <p class="cAF">see under <a title="BNF:target-block: Tocilizumab" href="202659.htm#_204106">Cytokine Modulators</a> above</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">predisposition to infection or history of recurrent or chronic infection; interrupt treatment if serious infection occurs; history of intestinal ulceration or diverticulitis; monitor hepatic transaminases every 4–8 weeks for
first 6 months, then every 12 weeks; monitor
neutrophil and platelet counts 4–8 weeks after starting treatment
and then as indicated; low platelet or absolute neutrophil
count (discontinue if absolute neutrophil count less than 0.5 × 10<sup>9</sup>/litre or platelet count less than 50 × 10<sup>3</sup>/microlitre); monitor lipid profile 4–8 weeks after starting treatment and then
as indicated; monitor for demyelinating
disorders; <b>interactions</b>: Appendix 1
(tocilizumab)</p><div class="cAV"><h3>Tuberculosis</h3> <p class="cAX">Patients should be evaluated
for tuberculosis before treatment. Patients with latent
tuberculosis should be treated with standard therapy (<a title="BNF:sub-section: Antituberculosis drugs" href="3899.htm#_3899">section 5.1.9</a>) before starting tocilizumab</p></div><div class="cAV"><h3>Counselling</h3> <p class="cAX">Patients should be advised
to seek immediate medical attention if symptoms of infection occur,
or if symptoms of diverticular perforation such as abdominal pain,
haemorrhage, or fever accompanying change in bowel habits occur</p></div></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">severe active infection (see also Cautions); do not initiate if absolute neutrophil count
less than 2 × 10<sup>9</sup>/litre (see also Cautions)</p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">manufacturer advises caution (see also Dose below)</p></div><div class="cAF"><h2>Renal impairment</h2> <p class="cAF">manufacturer advises monitor renal function closely in
moderate or severe impairment</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">manufacturer advises avoid unless essential (toxicity
in <i>animal</i> studies); effective contraception required
during and for 3 months after treatment</p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">manufacturer advises use only if potential benefit
outweighs risk —no information available</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">abdominal pain, mouth ulceration, gastritis, raised
hepatic transaminases; dizziness, peripheral oedema, hypertension,
hypercholesterolaemia; headache; infection (including upper respiratory-tract
infection); antibody formation, hypersensitivity, leucopenia, neutropenia;
rash, pruritus; <i>less commonly</i> gastric ulcer, gastro-intestinal
perforation, hypertriglyceridaemia, hypothyroidism, nephrolithiasis,
infusion related reactions, anaphylaxis, and thrombocytopenia also
reported</p></div><div class="cAF"><h2>Dose</h2> <p class="cR"><span class="cU">By intravenous infusion</span>, <span class="cAK">adult</span> over 18 years, 8 mg/kg (max. 800 mg) once every
4 weeks; for details of dose adjustment in patients with liver enzyme
abnormalities, or low absolute neutrophil or platelet count, consult
product literature</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li class="jN" id="_204108" style="margin: 0 0 0 20px;"><h1 class="title">RoActemra®<span> (<a href="appendix-112803-R.htm#m254">Roche</a>)</span> <a href="204285.htm" title="Report adverse reaction(s)"><img class="cK" src="images/blacktri_s.png" alt="Black triangle" /></a> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Concentrate for intravenous infusion</span>, tocilizumab 20 mg/mL, net price 4 mL (80-mg) vial = £102.40, 10 mL
(200-mg) vial = £256.00, 20 mL (400-mg) vial = £512.00. 
    Label:
    Alert card, counselling, see above</div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="129937.htm">Previous: RITUXIMAB</a> | <a class="top" href="204108.htm#">Top</a> | <a accesskey="]" href="5307.htm">Next: Sulfasalazine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>